

# Notes of the Formulary Management Group

Held on	Tuesday 4 <sup>th</sup> October 2016			Jubilee House, Room 3	
Members	Attended	Apologies	Absent	Designation	Abbreviation
	✓			Head of Medicines Management (Chair)	(C)
	✓			Prescribing Adviser	(PA)
	✓			GP Lead for Medicines Management	(GP)
	✓			WHT Pharmacist	(WHTP)
	✓			Primary Care Pharmacist	(PCP)
		✓		Clinical Nurse Specialist	(CNS)
			✓	Nurse Non-Medical Prescriber	(NNMP)
	✓			DWMHPT Pharmacist	(DWMHP)
		✓		DWMHPT Deputy Pharmacist	(DWMHDP)
		✓		Healthcare Governance	(HG)
			✓	Chief Pharmacist Walsall Healthcare Trust	(CPWHT)
			✓	District Nurse Team Leader Walsall Healthcare Trust	(DNTL)
		✓		Patient Representative	(PR)
	✓			Note Taker	

	Agenda item	Actions
1	<p><b><u>Welcome And Apologises (Declarations of AOB)</u></b></p> <p>Everyone was welcomed to the October Formulary Management meeting.</p>	
2	<p><b><u>Minutes Of Last Meeting</u></b> - Consent agenda accepted.</p> <p>The minutes from the last meeting in September were declared a true and accurate record, subject to the following amendment.</p> <ul style="list-style-type: none"> <li>• Gevoja was confirmed a completed action at the previous meeting but is back on the agenda for the meeting.</li> </ul>	
3	<p><b><u>Matters Arising/Actions Sheet</u></b></p> <p><b>Degludec</b> – C advised an audit is no longer required and a guidance sheet will be produced in its place.</p> <p><b>Ferinject</b> – An invitation has been sent to the Dr and his team to attend and present the application at the November meeting – No response has been received back.</p> <p><b>ABX Formulary</b> – Conversations between the Microbiology team and PCP are currently taking place regarding the proposed author of the new document – PCP to have finalised within the next two weeks.</p> <p><b>NOACs</b> - PCP confirmed the document is with the Dr but still awaiting a response.</p> <p><b>Keel Competency Training</b> – No further updates from C.</p> <p><b>Quarterly Declarations of Interest</b> – Quarterly forms have been sent out for October by the note taker.</p> <p><b>Vortioxitene</b> – An extension on the audit date was required and will now be presented at the November meeting.</p> <p><b>Obesity Drugs</b> – No further updates - Still awaiting confirmation.</p>	

**Next meeting – Tuesday 1<sup>st</sup> November 2016, 1:00 – 3:30pm at Jubilee House, Room 1**

# Notes of the Formulary Management Group

	<p style="text-align: center;"><b>Action</b> – C to chase up for an update.</p> <p><b>Renal Function and RAS Drug Combinations</b> - C agreed this item has been completed and will be removed from the action sheet.</p> <p><b>OPEP Funding for this year</b> – Further updates are still required.</p> <p style="text-align: center;"><b>Action</b> – C to contact the Community team for an update.</p> <p><b>Gevoxa</b> – C agreed this item has been completed and will be removed from the action sheet.</p> <p><b>Guanfacine (Revised ESCA)</b> – C agreed this item has been completed and will be removed from the action sheet.</p> <p><b>Adult ADHD Shared Care Protocol</b> – C still waiting for some guidance back from the Senior Commissioning Development Manager – Protocol still to be approved.</p> <p><b>Formulary Review Process</b></p> <ul style="list-style-type: none"> <li>• <b>Baby Milks Formulary</b> – Further work required - Conversations are taking place with the Community staff.</li> <li>• <b>BD Autoschild Pen Needles</b> – A draft form ‘Do not prescribe’ list has being developed and awaiting consultation to commence.</li> <li>• <b>Branded Lamotrigine/Lamictal</b> – Discussions are still undergoing.</li> </ul> <p style="text-align: center;"><b>Action</b> – PCP to invite the team to the meeting in November.</p> <p><b>Esyma</b> - C still waiting for the template.</p> <p><b>Ceftobiprole to MMQT</b> - C agreed this item has been completed and will be removed from the action sheet.</p> <p><b>Optimise RX message for topical Miconazole</b> – No further updates were provided at the meeting.</p> <p style="text-align: center;"><b>Action</b> – C to check the progress and will provide an update at the November meeting.</p> <p><b>Drug Safety Updates in Newsletter</b> – C agreed this item has been completed and will be removed from the action sheet.</p> <p><b>‘Do Not Prescribe’ List</b> – A discussion took place regarding the draft list and various suggestions/improvements were put forward – C to address the proposals.</p> <p><b>Denosumab for male Osteoporosis</b> – No further updates were brought to the meeting.</p> <p style="text-align: center;"><b>Action</b> - WHTP to follow up and provide an update at the next meeting in November.</p>	
4	<p><b><u>Declarations of Interest</u></b></p> <p>Quarterly declaration of interest forms have been sent out by the note taker.</p>	
5	<p><b><u>NICE Technology Appraisal</u></b></p> <p>None</p>	
6	<p><b><u>Non NICE TA Drugs/Devices – Full Applications</u></b></p> <p>None</p>	

# Notes of the Formulary Management Group

7	<p><b><u>Non – NICE TA Drug/Devices - Short Applications</u></b></p> <p><b>Application 138. Tapentadol</b> – A complex discussion took place regarding application 138. The drug is currently prescribed for chronic pain; the new proposal is for the drug to be prescribed for COPD (Chronic Obstructive Pulmonary Disease) patients suffering with chronic pain.</p> <p>Within the hospital the drug is restricted to a Pain Management Consultant only, with the new proposal this will allow the Respiratory Consultant to prescribe alongside.</p> <p>It was agreed to not approve the application on this occasion and to obtain more clarity regarding their views on prescribing.</p> <p><b>Action</b> – C to draft up a response to the hospital following the comments made from the meeting.</p> <p><b>Application 139. Strivit Vitamin D</b> – After a discussion the application was approved by the committee.</p> <p><b>Application 140. Reletrans</b> – It was agreed by the committee that further work was required around the application. The application is to be checked against Blutech for cost implications before the final approval by the committee.</p>	
8	<p><b><u>Drug Safety Update</u></b></p> <ul style="list-style-type: none"> <li>• Levonorgestrel – Containing Emergency Hormonal Contraception</li> <li>• Posaconazole (Noxafil)</li> <li>• Idelalisib (Zydelig ▼)</li> </ul> <p>The above items were not discussed at the meeting.</p>	
9	<p><b><u>Horizon Scanning</u></b></p> <ul style="list-style-type: none"> <li>• NICE Forward Planner – August 2016</li> <li>• Do not print</li> </ul> <p>The above items were not discussed at the meeting.</p>	
10	<p><b><u>Appeals</u></b></p> <p>None</p>	
11	<p><b><u>Formulary Updates</u></b></p> <ul style="list-style-type: none"> <li>• NOAC Interactive Guidelines</li> </ul> <p>The above item was not discussed at the meeting.</p>	
12	<p><b><u>Formulary Breach</u></b></p> <ul style="list-style-type: none"> <li>• Victoza 1</li> <li>• Victoza 2</li> <li>• Victoza 3</li> <li>• Lurasidone (Antipsychotic)</li> </ul> <p>The above items were not discussed at the meeting.</p>	
13	<p><b><u>Recommendations to JMMC</u></b></p> <p>None</p>	

